In contrast, CCNA2-H/E2F1-H, PPP2R1Amu, and/or FBXW7mu were associated with significantly compromised recurrence-free survival among patients with low- and high-risk EEC, suggesting that patients with MHR ECPPF likely are insensitive to adjuvant therapies (ie, radiotherapy and/or PbCT). The gene discussed is CCNA2; the disease is exstrophy-epispadias complex.